| Symbol | MNOV |
|---|---|
| Name | MEDICINOVA INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 4275 EXECUTIVE SQUARE, LA JOLLA, CA 92037 |
| Telephone | 858-373-1500 |
| Fax | — |
| — | |
| Website | https://www.medicinova.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001226616 |
| Description | MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firms current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of the small molecule therapeutics segments. Additional info from NASDAQ: |
Director Nagao Hideki 🟢 acquired 44.5K shares (1 derivative) of MEDICINOVA INC (MNOV) at $1.36 Transaction Date: Jun 23, 2026 | Filing ID: 005111
Read moreDirector Lemerond Nicole 🟢 acquired 44.5K shares (1 derivative) of MEDICINOVA INC (MNOV) at $1.36 Transaction Date: Jun 23, 2026 | Filing ID: 005110
Read moreDirector BEAVER CAROLYN 🟢 acquired 44.5K shares (1 derivative) of MEDICINOVA INC (MNOV) at $1.36 Transaction Date: Jun 23, 2026 | Filing ID: 005109
Read moreMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
Read moreMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
Read moreNew Form ARS - MEDICINOVA INC <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001193125-26-191932 <b>Size:</b> 724 KB
Read moreNew Form DEF 14A - MEDICINOVA INC <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001193125-26-191866 <b>Size:</b> 2 MB
Read moreNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
Read moreNew Form PRER14A - MEDICINOVA INC <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001193125-26-164217 <b>Size:</b> 2 MB
Read more